Georgios  Terzis net worth and biography

Georgios Terzis Biography and Net Worth

George Terzis oversees all Cosmos’ financial functions. Prior to this role, George has served as an Executive Consultant to several multinational advisory firms where, he achieved commitments of more than €50 mil of funding to numerous investments in various industries. George holds an MBA from Alba Graduate Business school and a BSc in Financial Management from University of Attica, and he is certified as an independent valuator of corporations and private investments by the European Commission.

What is Georgios Terzis' net worth?

The estimated net worth of Georgios Terzis is at least $836.04 thousand as of June 16th, 2026. Terzis owns 2,235,398 shares of Cosmos Health stock worth more than $836,039 as of September 28th. This net worth approximation does not reflect any other assets that Terzis may own. Learn More about Georgios Terzis' net worth.

How do I contact Georgios Terzis?

The corporate mailing address for Terzis and other Cosmos Health executives is 5 Agiou Georgiou, Pilea, Thessaloniki, J3, 55438. Cosmos Health can also be reached via phone at (312) 536-3102 and via email at [email protected]. Learn More on Georgios Terzis' contact information.

Has Georgios Terzis been buying or selling shares of Cosmos Health?

Georgios Terzis has not been actively trading shares of Cosmos Health during the last ninety days. Most recently, on Tuesday, June 16th, Georgios Terzis bought 168,135 shares of Cosmos Health stock. The stock was acquired at an average cost of $0.25 per share, with a total value of $42,033.75. Following the completion of the transaction, the chief financial officer now directly owns 2,235,398 shares of the company's stock, valued at $558,849.50. Learn More on Georgios Terzis' trading history.

Who are Cosmos Health's active insiders?

Cosmos Health's insider roster includes Grigorios Siokas (CEO), Georgios Terzis (CFO), and Georgios Terzis (CFO). Learn More on Cosmos Health's active insiders.

Are insiders buying or selling shares of Cosmos Health?

During the last twelve months, Cosmos Health insiders bought shares 21 times. They purchased a total of 4,907,168 shares worth more than $1,747,302.54. The most recent insider tranaction occured on July, 30th when CEO Grigorios Siokas bought 349,825 shares worth more than $69,965.00. Insiders at Cosmos Health own 26.2% of the company. Learn More about insider trades at Cosmos Health.

Information on this page was last updated on 7/30/2026.

Georgios Terzis Insider Trading History at Cosmos Health

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/16/2026Buy168,135$0.25$42,033.752,235,398View SEC Filing Icon  
12/20/2024Buy85,778$0.58$49,751.24727,263View SEC Filing Icon  
See Full Table

Georgios Terzis Buying and Selling Activity at Cosmos Health

This chart shows Georgios Terzis's buying and selling at Cosmos Health by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Cosmos Health Company Overview

Cosmos Health logo
Cosmos Health Inc. manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, Cayman Islands, and Cyprus. It offers medicines, OTC medicines, nutraceutical products, vitamins, minerals and dietary, health care products, medical devices, baby products, and others under the Sky Premium Life and Mediterranation brand names. The company serves wholesale distributors and other healthcare providers, such as clinics, government agencies, independent retail and specialty pharmacies and independent specialty distributors. It sells its products through independent wholesale distributors. Cosmos Health Inc. was incorporated in 2009 and is headquartered in Chicago, Illinois.
Read More

Today's Range

Now: $0.37
Low: $0.36
High: $0.40

50 Day Range

MA: $0.24
Low: $0.18
High: $0.41

2 Week Range

Now: $0.37
Low: $0.16
High: $1.32

Volume

3,067,272 shs

Average Volume

4,323,095 shs

Market Capitalization

$37.64 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

4.8